Login to Your Account

Merck Serono, Affectis Ally to Advance Neurology Candidates

By Catherine Shaffer

Thursday, June 9, 2011
Affectis Pharmaceuticals AG signed on with Merck Serono to develop neurology compounds targeting P2X7 receptors, a calcium channel thought to play a role in neuroprotection. Affectis has been developing the P2X7 receptor as a target for depression and some other related indications.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription